- Home
- ATAT vs PCVX Comparison
ATAT vs PCVX Comparison
Compare ATAT & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAT | PCVX |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 6.1B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATAT | PCVX |
|---|---|---|
| Price | $36.54 | $58.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $46.16 | ★ $98.33 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $37.53 | N/A |
| Revenue Next Year | $24.22 | N/A |
| P/E Ratio | $26.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.50 | $28.09 |
| 52 Week High | $43.17 | $76.61 |
Technical Indicators
Market Signals| Indicator | ATAT | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 52.93 |
| Support Level | $34.23 | $42.30 |
| Resistance Level | $37.00 | $65.00 |
| Average True Range (ATR) | 1.38 | 3.08 |
| MACD | -0.34 | -0.53 |
| Stochastic Oscillator | 27.58 | 35.38 |
Price Performance
Historical ComparisonAbout ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.